Oxford Gene Technology Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oxford Gene Technology Ltd.
Oxford Gene Technology has appointed its former head of R&D, John Anson, as CEO and brought in a new head of regulatory affairs, Paul Kenny, as the company shifts resources to the molecular diagnostics market.
Oxford Gene Technology announced May 31 that it will become a wholly owned subsidiary of Sysmex, the Japanese in vitro diagnostics company that will gain entry into the cytogenetics market with OGT's fluorescence in situ hybridization and array comparative genomic hybridization products.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February through March 2014.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced February-March 2014.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries